Verastem
A development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer.
The American company's pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition.
Latest Verastem News & Features
31 May 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze